TL;DR
This study introduces a novel in vitro maturation (IVM) system using ovarian support cells (OSCs) derived from human induced pluripotent stem cells (hiPSCs). This OSC-IVM approach significantly improves the maturation rate of immature human oocytes and leads to a higher rate of healthy, euploid blastocyst formation compared to existing IVM methods, offering a promising advancement for fertility treatments.
What Problem Does This Paper Address?
Infertility affects a significant portion of the population, and assisted reproductive technologies (ART) like IVF and IVM are crucial for treatment. While IVM offers an alternative to conventional ovarian stimulation (COS), it has historically suffered from variable success rates and lower developmental potential of the resulting oocytes. Current IVM methods often struggle to produce oocytes with robust developmental capacity, and some newer approaches are limited to non-standard protocols. This paper addresses the need for a more effective and reliable IVM system that can yield high-quality oocytes, particularly from abbreviated stimulation cycles, which are often preferred for their reduced cost and side effects.
Methods
The core innovation in this study is the development and application of an in vitro maturation (IVM) system co-cultured with human induced pluripotent stem cell-derived ovarian support cells (hiPSC-OSCs). These OSCs were generated through a transcription factor-directed protocol and mimic natural ovarian granulosa cells.
The study involved three main experimental comparisons:
- OSC Activity: To determine if the OSCs themselves were the active component in improving maturation, comparing OSC-IVM to media alone or media with other cell types (fetal ovarian somatic cells - FOSCs).
- OSC Clinical Relevance (IVM only): To compare the efficacy of the OSC-IVM system against a commercially available IVM medium (Medicult IVM) for oocyte maturation.
- OSC Clinical Relevance (Embryo Formation): To assess the developmental competence of oocytes matured using OSC-IVM by evaluating fertilization, cleavage, blastocyst formation, and euploidy rates compared to the commercial IVM control.
Immature oocytes were retrieved from donors undergoing abbreviated gonadotropin stimulation. These oocytes were then cultured in either the OSC-IVM system or control conditions. Maturation rates (Metaphase II - MII), oocyte morphology (Total Oocyte Score - TOS), fertilization, cleavage, blastocyst formation, and preimplantation genetic testing for aneuploidy (PGT-A) were assessed. Additionally, the epigenetic profiles of resulting blastocysts were analyzed.
Datasets
The study utilized oocytes retrieved from 67 human oocyte donors aged 19-37 years, recruited from multiple fertility clinics. For embryo epigenetic analysis, five euploid blastocysts generated from the OSC-IVM condition were compared with eight donated euploid blastocysts from conventional controlled ovarian stimulation (COS) cycles. External reference data from previous studies on COS and CAPA-IVM (another IVM approach) were also used for epigenetic comparisons. No new benchmarks were introduced; rather, existing metrics and established protocols were used for evaluation.
Key Insights and Ideas
- hiPSC-derived OSCs are potent enhancers of oocyte maturation: The study clearly demonstrates that co-culturing immature oocytes with hiPSC-derived OSCs significantly boosts the rate at which they reach the mature MII stage. This suggests that OSCs provide crucial signals that promote nuclear and cytoplasmic maturation.
- Beyond maturation: improved developmental potential: The OSC-IVM system not only improves oocyte maturation but also leads to a higher rate of euploid blastocyst formation. This indicates that the matured oocytes are more developmentally competent and capable of forming healthy embryos.
- Epigenetic normalcy: Crucially, blastocysts derived from OSC-IVM show normal global and germline epigenetic profiles, comparable to those from conventional COS. This is a key indicator of their potential for healthy development and implantation, addressing a critical concern for IVM-derived embryos.
- Scalability and broad applicability: The OSC-IVM approach integrates well with existing ART laboratory procedures and uses a single source of hiPSCs, suggesting it is scalable, reproducible, and cost-effective, making it a promising candidate for widespread clinical adoption.
- Specificity of OSCs: The study suggests that the benefit comes from the engineered granulosa-like cells themselves, not just the general co-culture environment or other cell types like FOSCs.
Key Results
- MII Maturation Rate: OSC-IVM significantly improved MII formation rates by approximately 1.5x compared to media controls and commercially available IVM media. For instance, in Experiment 2, OSC-IVM achieved a 68% MII rate compared to 43% for commercial IVM (p=0.0349).
- Euploid Blastocyst Formation: OSC-IVM showed a statistically significant improvement in euploid day 5 or 6 blastocyst formation, with rates of 25% ± 7.5% compared to 11% ± 3.7% for the commercial IVM control (p=0.0349).
- Oocyte Morphology: While maturation rates improved, oocyte morphological quality (assessed by Total Oocyte Score) did not significantly differ between OSC-IVM and control groups, indicating no detrimental effect on quality.
- Epigenetic Profile: Blastocysts generated via OSC-IVM exhibited similar global and germline methylation profiles to those from conventional COS, suggesting normal epigenetic development.
Limitations and Future Work
- Basic Research Study: The authors acknowledge that the study's nature as a basic research study limits generalizability, and future randomized clinical trials are needed to establish the approach's clinical value.
- Oocyte Maturation State: Due to the use of abbreviated stimulation cycles, the precise initial maturation state of oocytes prior to IVM could not be empirically assessed while preserving cumulus-oocyte connections.
- Sample Size: While efforts were made for equitable distribution, slight imbalances in GV/MI/MII input distribution and overall small sample sizes in some comparisons are noted as limitations. Larger studies are recommended.
- Mechanism of Action: Further research is needed to precisely determine the mechanism by which OSCs promote IVM, including identifying specific secreted factors and environmental changes.
- Clinical Utility Validation: The ultimate validation of the approach's clinical utility will be its ability to generate healthy live births, which requires further clinical evaluation.
- Comparison to Other IVM: While OSC-IVM showed promise, direct comparisons with other advanced IVM techniques like CAPA-IVM were not performed in this study, and future work could explore these differences.
Summary updated